In a bid to break into the CDMO business at one of its most lucrative angles, India's Granules is snapping up Swiss contract ...

Granules India has acquired Swiss CDMO company Senn Chemicals AG for Rs 192 crore, expanding its peptide therapeutics market ...

Generic drugmaker Granules India is foraying into the peptide segment and contract development and manufacturing organisation ...

Granules India advanced 1.95% to Rs 519 after the company said that its board has approved to acquire 100% stake in Senn Chemicals AG, a Switzerland based company, for a total consideration of Rs 192.

Granules India enters peptide segment and CDMO business by acquiring Senn Chemicals AG: Our Bureau, Bengaluru Monday, February 24, 2025, 12:20 Hrs [IST] Granules India, a generic ...

Zydus Lifesciences: The company and its subsidiaries received final approval from the United States Food and Drug Administration (US FDA) to manufacture Ibuprofen and Famotidine tablets, 800 mg/26.6 ...

With this acquisition, Granules gains capabilities in high-growth peptide-based therapeutics. It also aims to enter the ...

Alzheimer's disease is at the center of a revolutionary theory in neuroscience, where the mysteries of the human brain ...

Granules India acquires Senn Chemicals AG, expanding into peptide therapeutics and CDMO capabilities for global growth.

Senn develops and manufactures, peptides and peptides-based applications for its global customers, providing contract research, development, and manufacturing services.